Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Accumulated Expenses: 2014-2017

Historic Accumulated Expenses for Viking Therapeutics (VKTX) over the last 4 years, with Dec 2017 value amounting to $22,000.

  • Viking Therapeutics' Accumulated Expenses was N/A to $34,000 in Q1 2018 from the same period last year, while for Mar 2018 it was $34,000, marking a year-over-year change of. This contributed to the annual value of $22,000 for FY2017, which is 36.95% down from last year.
  • As of FY2017, Viking Therapeutics' Accumulated Expenses stood at $22,000, which was down 36.95% from $34,894 recorded in FY2016.
  • Over the past 5 years, Viking Therapeutics' Accumulated Expenses peaked at $183,611 during FY2015, and registered a low of $22,000 during FY2017.
  • Moreover, its 3-year median value for Accumulated Expenses was $34,894 (2016), whereas its average is $80,168.
  • In the last 5 years, Viking Therapeutics' Accumulated Expenses spiked by 137.77% in 2015 and then tumbled by 81.00% in 2016.
  • Viking Therapeutics' Accumulated Expenses (Yearly) stood at $77,222 in 2014, then soared by 137.77% to $183,611 in 2015, then slumped by 81.00% to $34,894 in 2016, then plummeted by 36.95% to $22,000 in 2017.